Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribut...

Full description

Bibliographic Details
Main Authors: Hideo Oishi, MD, Ryota Morimoto, MD, PhD, Yoshie Shimoyama, MD, PhD, Kei Kuroda, MD, Toru Urata, MD, Toru Kondo, MD, PhD, Takahiro Okumura, MD, PhD, Yasuko K. Bando, MD, PhD, Masashi Akiyama, MD, PhD, Toyoaki Murohara, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:JACC: Case Reports
Subjects:
myocardial injury
pembrolizumab
vasculitis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666084920309037

Internet

http://www.sciencedirect.com/science/article/pii/S2666084920309037

Similar Items